COLUMBIA, S.C. (April 30, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL). It is part of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.
With an anticipated Beyond Use Date (BUD) of 150 days, the single-dose syringe of Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL) can be stored at room temperature and is already diluted, labeled with cautionary statements, color-coded to ASTM drug class standards, and ready to be administered within OR and acute care settings. The standardized concentration in a prefilled syringe negates the need for in-hospital compounding and helps decrease the possibility of sub or supra therapeutic doses for patients.
“Ritedose serves as the missing link for our hospital clients in the supply chain disruptions they often experience,” said Ritedose President and CEO Jody Chastain. “Our competitive pricing and outsourcing model can make a significant difference in efficiency for hospitals.”
Founded in 1995 in Columbia, South Carolina, The Ritedose Corporation is an industry leader in the aseptic manufacturing and liquid packaging of respiratory inhalation products, and utilizes proven Blow-Fill-Seal (BFS) equipment and processes to ensure efficient, consistent and safe dosage delivery. The company’s 25-year track record includes the delivery of more than 8 billion doses since 2012 without a single recall, and its current capacity is 1.7 billion units annually. In 2020, The Ritedose Corporation was selected as a subcontractor to ApiJect for the production of single-dose prefilled syringes intended for administering COVID-19 vaccines.